Clinical Trial Update: Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study [Phase 2]

View source ↗

Summary

Phase 2 translational and biomarker study evaluating durvalumab after chemoradiotherapy for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING